Full Press Release Details
CTD Holdings Closes $1.725 Million Private Placement
Investment builds company strength in preparation for clinical
ALACHUA, Fla., July 22, 2014 - CTD Holdings, Inc. (OTCQB:CTDH),
a manufacturer and distributor of cyclodextrins for the pharmaceutical, medical device, cosmetics, and other markets, announced
today that it has closed on a Private Placement with a group of qualified private investors led by Novit L.P., an investment arm
The transaction involved the signing of a Securities Purchase Agreement
under which CTD Holdings issued 1,725,000 shares of Common Stock at a price per share of $1.00, resulting in a $1,725,000 capital
infusion to the Company. There were no other conditions connected to the issuance of the shares.
Scarsdale Equities, LLC acted as financial advisor and exclusive
placement agent of the Company in connection with the Securities Purchase Agreement.
A complete description of the transaction can be found in the Current
Report on Form 8-K filed with the Securities and Exchange Commission in connection with this transaction.
"This vote of confidence from our existing shareholders is
especially gratifying," said Dr. Jeffrey Tate, President and CEO. "They share our vision for saving the lives of children
with Niemann-Pick Type C by developing this treatment we believe will prove effective against this devastating fatal disease. It
continues to build the strength needed for the challenge of clinical trials ahead."
In 2010 the U.S. Food &
Drug Administration designated Trappsol(R) Cyclo(TM) as an orphan drug for the treatment of Niemann-Pick Type C disease, a rare
and fatal genetic condition that typically develops in children under 10 years of age. In the U.S. treatment with Trappsol(R) Cyclo(TM)
is supervised by a physician holding an approved Investigational New Drug Protocol.
The proceeds of the transaction will be used primarily for the development
of the Trappsol(R) Cyclo(TM) orphan drug, including filing the Drug Master File with U.S. FDA, planning for clinical trials in
Europe and the U.S., and development of the third-generation product.
The CTD Holdings, Inc.
Family of Companies distributes and manufactures the trademarked Trappsol(R) and Aquaplex(R) cyclodextrins, cyclodextrin derivatives,
and cyclodextrin complexes for the research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology,
Inc. is developing Trappsol(R) Cyclo(TM), an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare
and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for
the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex(R) cyclodextrin complexes. CTD, Inc. supplies
cyclodextrins to researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide
variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and
commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites:
Safe Harbor Statement:
This press release contains "forward-looking statements"
about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not
historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking
statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results
in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence
the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success
in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical
grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange
Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes
no obligation to update or revise any forward-looking statements as a result of new information or future events.
Wendy Tanaka, (415) 369-8447,
Thomas Mulligan, (212)
573-6100, Ext. 395, tmulligan@sitrick.com
Source: CTD Holdings, Inc.